<DOC>
	<DOCNO>NCT02546791</DOCNO>
	<brief_summary>This retrospective , multicenter , descriptive analysis patient diagnosis chronic myeloid leukemia , treat dasatinib least 45 day . The study include 100 patient treated different public center Mexican Republic .</brief_summary>
	<brief_title>Frequency Severity Pleural Effusion Associated With Use Dasatinib Patients With Chronic Myeloid Leukemia . A Descriptive , Mexican Multicenter Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Men woman â‰¥15 year age Diagnosis chronic myeloid leukemia phase use dasatinib time January 2008 November 2014 Have receive dasatinib part firstline secondline treatment least 45 day Patients receive dasatinib part clinical trial Patients complete data data collection sheet Patients medical record available moment data verification</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>